TScan Therapeutics, Inc.

TScan Therapeutics, Inc.

Healthcare

NASDAQ:TCRX · NASDAQ Global Market

Market Cap $55.71M Beta 1.03 P/E (TTM) -1.0
$0.85 -1.28%

-$0.01 today

52W Low $0.88High $2.57

Vol 0.81M · Avg 0.82M

EPS (TTM) -$0.96Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

-44.93%

Period High

$2.52

Period Low

$0.85

Latest

$0.85

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health
Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc.

NASDAQ:RLMD

$487.67M

Immunic, Inc.

Immunic, Inc.

NASDAQ:IMUX

$136.78M

Vaxart, Inc.

Vaxart, Inc.

NASDAQ:VXRT

$135.55M

Fortress Biotech, Inc.

Fortress Biotech, Inc.

NASDAQ:FBIO

$92.02M

Adicet Bio, Inc.

Adicet Bio, Inc.

NASDAQ:ACET

$75.25M

XBiotech Inc.

XBiotech Inc.

NASDAQ:XBIT

$71.34M

PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals, Inc.

NASDAQ:PMVP

$59.20M

AC

Acrivon Therapeutics, Inc. Common Stock

ACRV

$46.70M

NT

Nutriband Inc.

NTRB

$41.21M

LI

Lite Strategy, Inc.

LITS

$25.22M

What is the latest TCRX filing?

The latest filing shown is 8-K dated May 22, 2026.

How many recent filings does TCRX have?

Intrinsic Alpha currently shows 20 recent filings for TCRX.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.